Financings
Revive Therapeutics Announces Proposed Private Placement
Cash-burning micro-cap biotech raises survival capital via dilutive private placement while pursuing repurposed drug for nerve agents and infectious diseases.
Executive Summary
- Revive Therapeutics announced a proposed private placement of up to 31,250,000 units at $0.032 per unit.
- Gross proceeds are targeted at approximately $1,000,000.
- Each unit comprises one common share and one common share purchase warrant exercisable at $0.05 per share for 36 months.
- Proceeds will be used for working capital.
- The transaction may close in tranches, subject to customary conditions, with a 4-month and 1-day hold period for investors.
- Finder compensation is set at 8.0% cash plus 8.0% in warrants with identical terms.
Material Impact
- The company is in a severe liquidity crisis, with a going concern warning, negative equity of -$4.0M, and only ~$12,665 to $22,665 in cash.
- The $1M raise is strictly a survival mechanism. It covers a fraction of the $4.15M working capital deficiency and provides roughly 6 months of runway based on a ~$0.17M monthly burn rate.
- Dilution is immediate and significant: ~7.2% from the share issuance, plus additional dilution from the warrants and finder warrants.
- The placement price of $0.032 is at a slight premium to the recent $0.03 trading range, but the out-of-the-money warrants ($0.05) limit immediate upside dilution pressure.
- This does not alter the fundamental risk profile; it merely extends the timeline to the next inevitable capital raise.
RVV · Price
Company Overview
- Revive Therapeutics is a clinical-stage biotechnology company focused on drug repurposing and medical countermeasures.
- Core asset: Bucillamine, a thiol-based drug with over 30 years of clinical history in Japan and South Korea for rheumatoid arthritis.
- Strategic pivot: Expanding bucillamine into infectious diseases, nerve-agent exposure, chemical threats, and long COVID.
- Secondary pipeline: Psilocybin therapeutics, currently paused pending financing.
- Business model: Relies on intellectual property expansion, government partnerships (e.g., DRDC), and potential licensing or procurement contracts rather than direct commercial sales.
More from Revive Therapeutics Ltd.
Jun 08, 2026 · 08:04